121 related articles for article (PubMed ID: 25541745)
21. Metal Coordination Is Crucial for Geranylgeranyl Diphosphate Synthase-Bisphosphonate Interactions: A Crystallographic and Computational Analysis.
Lisnyansky M; Yariv E; Segal O; Marom M; Loewenstein A; Ben-Tal N; Giladi M; Haitin Y
Mol Pharmacol; 2019 Nov; 96(5):580-588. PubMed ID: 31427399
[TBL] [Abstract][Full Text] [Related]
22. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
23. Insights about the structure of farnesyl diphosphate synthase (FPPS) and the activity of bisphosphonates on the proliferation and ultrastructure of Leishmania and Giardia.
Gadelha APR; Brigagao CM; da Silva MB; Rodrigues ABM; Guimarães ACR; Paiva F; de Souza W; Henriques C
Parasit Vectors; 2020 Apr; 13(1):168. PubMed ID: 32248823
[TBL] [Abstract][Full Text] [Related]
24. Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes.
Mao J; Mukherjee S; Zhang Y; Cao R; Sanders JM; Song Y; Zhang Y; Meints GA; Gao YG; Mukkamala D; Hudock MP; Oldfield E
J Am Chem Soc; 2006 Nov; 128(45):14485-97. PubMed ID: 17090032
[TBL] [Abstract][Full Text] [Related]
25. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
26. Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
Scrima M; Lauro G; Grimaldi M; Di Marino S; Tosco A; Picardi P; Gazzerro P; Riccio R; Novellino E; Bifulco M; Bifulco G; D'Ursi AM
J Med Chem; 2014 Sep; 57(18):7798-803. PubMed ID: 25184810
[TBL] [Abstract][Full Text] [Related]
27. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
28. Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.
Yin F; Cao R; Goddard A; Zhang Y; Oldfield E
J Am Chem Soc; 2006 Mar; 128(11):3524-5. PubMed ID: 16536518
[TBL] [Abstract][Full Text] [Related]
29. Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors.
Liu J; Liu W; Ge H; Gao J; He Q; Su L; Xu J; Gu LQ; Huang ZS; Li D
Biochim Biophys Acta; 2014 Mar; 1840(3):1051-62. PubMed ID: 24246954
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Ling Y; Sahota G; Odeh S; Chan JM; Araujo FG; Moreno SN; Oldfield E
J Med Chem; 2005 May; 48(9):3130-40. PubMed ID: 15857119
[TBL] [Abstract][Full Text] [Related]
31. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
Dunford JE
Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
[TBL] [Abstract][Full Text] [Related]
32. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.
Rondeau JM; Bitsch F; Bourgier E; Geiser M; Hemmig R; Kroemer M; Lehmann S; Ramage P; Rieffel S; Strauss A; Green JR; Jahnke W
ChemMedChem; 2006 Feb; 1(2):267-73. PubMed ID: 16892359
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of new potent inhibitors of farnesyl pyrophosphate synthase.
Prokopenko V; Kovalishyn V; Shevchuk M; Kopernyk I; Metelytsia L; Romanenko V; Mogilevich S; Kukhar V
Curr Drug Discov Technol; 2014 Jun; 11(2):133-44. PubMed ID: 24818603
[TBL] [Abstract][Full Text] [Related]
35. New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.
Fernández D; Ramis R; Ortega-Castro J; Casasnovas R; Vilanova B; Frau J
J Comput Aided Mol Des; 2017 Jul; 31(7):675-688. PubMed ID: 28631130
[TBL] [Abstract][Full Text] [Related]
36. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
Leung CY; Park J; De Schutter JW; Sebag M; Berghuis AM; Tsantrizos YS
J Med Chem; 2013 Oct; 56(20):7939-50. PubMed ID: 23998921
[TBL] [Abstract][Full Text] [Related]
37. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation.
Sanchez VM; Crespo A; Gutkind JS; Turjanski AG
J Phys Chem B; 2006 Sep; 110(36):18052-7. PubMed ID: 16956297
[TBL] [Abstract][Full Text] [Related]
38. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure.
Park J; Lin YS; De Schutter JW; Tsantrizos YS; Berghuis AM
BMC Struct Biol; 2012 Dec; 12():32. PubMed ID: 23234314
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells.
Das S; Edwards PA; Crockett JC; Rogers MJ
Biochim Biophys Acta; 2014 Apr; 1841(4):569-73. PubMed ID: 24369118
[TBL] [Abstract][Full Text] [Related]
40. Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product.
Park J; Zielinski M; Magder A; Tsantrizos YS; Berghuis AM
Nat Commun; 2017 Jan; 8():14132. PubMed ID: 28098152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
